Characteristics of subtype III-A CRISPR-Cas system in Mycobacterium tuberculosis: An overview

被引：4

作者：

Hamdi, Insaf ^{[1
]}

Boni, Funmilayo ^{[1
]}

Shen, Qinglei ^{[1
]}

Moukendza, Liadrine ^{[1
]}

Peibo, Li ^{[2
]}

Jianping, Xie ^{[1
,2
]}

机构：

[1] Southwest Univ, Inst Modern Biopharmaceut,Sch Life Sci, State Key Lab Breeding Base Ecoenvironm & Bioreso, Key Lab Ecoenvironm Three Gorges Reservoir Reg,Min, Chongqing 400715, Peoples R China

[2] Southwest Univ, Publ Hlth Hosp, Chongqing Publ Hlth Med Ctr, Chongqing 400030, Peoples R China

来源：

INFECTION GENETICS AND EVOLUTION | 2023年 / 112卷

关键词：

Mycobacterium tuberculosis; CRISPR-Cas III-A; Reverse transcriptase (RT); Housekeeping nuclease-anti-CRISPR; CRISPRi; COMPLEX; RNA; BACTERIA; CLASSIFICATION; MECHANISMS; KNOCKDOWN; INSIGHTS; ROLES;

D O I：

10.1016/j.meegid.2023.105445

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

CRISPR-Cas systems are the only RNA- guided adaptive immunity pathways that trigger the detection and destruction of invasive phages and plasmids in bacteria and archaea. Due to its prevalence and mystery, the Class 1 CRISPR-Cas system has lately been the subject of several studies. This review highlights the specificity of CRISPR-Cas system III-A in Mycobacterium tuberculosis, the tuberculosis-causing pathogen, for over twenty years. We discuss the difference between the several subtypes of Type III and their defence mechanisms. The antiCRISPRs (Acrs) recently described, the critical role of Reverse transcriptase (RT) and housekeeping nuclease for type III CRISPR-Cas systems, and the use of this cutting-edge technology, its impact on the search for novel anti-tuberculosis drugs.

引用

页数：11

共 50 条

[31] Functional Characterization of Type III-A CRISPR-Cas in a Clinical Human Methicillin-R Staphylococcus aureus Strain
Li, Yang
Mikkelsen, Kasper
Lluch i Grane, Oleguer
Wang, Zhenyu
Tang, Yuanyue
Jiao, Xinan
Ingmer, Hanne
Hoyland-Kroghsbo, Nina Molin
Li, Qiuchun
CRISPR JOURNAL, 2021, 4 (05): : 686 - 698
[32] Non-specific degradation of transcripts promotes plasmid clearance during type III-A CRISPR-Cas immunity
Rostol, Jakob T.
Marraffini, Luciano A.
NATURE MICROBIOLOGY, 2019, 4 (04) : 656 - 662
[33] Crystal Structures of Csm2 and Csm3 in the Type III-A CRISPR-Cas Effector Complex
Takeshita, Daijiro
Sato, Momoe
Inanaga, Hideko
Numata, Tomoyuki
JOURNAL OF MOLECULAR BIOLOGY, 2019, 431 (04) : 748 - 763
[34] RNA and DNA Targeting by a Reconstituted Thermus thermophilus Type III-A CRISPR-Cas System (vol 12, e0170552, 2017)
Liu, Tina Y.
Iavarone, Anthony T.
Doudna, Jennifer A.
PLOS ONE, 2017, 12 (04):
[35] Type III-A CRISPR-Cas Csm Complexes: Assembly, Periodic RNA Cleavage, DNase Activity Regulation, and Autoimmunity
Jia, Ning
Mo, Charlie Y.
Wang, Chongyuan
Eng, Edward T.
Marraffini, Luciano A.
Patel, Dinshaw J.
MOLECULAR CELL, 2019, 73 (02) : 264 - +
[36] Crystal Structure of the Csm3-Csm4 Subcomplex in the Type III-A CRISPR-Cas Interference Complex
Numata, Tomoyuki
Inanaga, Hideko
Sato, Chikara
Osawa, Takuo
JOURNAL OF MOLECULAR BIOLOGY, 2015, 427 (02) : 259 - 273
[37] The CRISPR-Cas system in molecular diagnostics
Song, Rao
Chen, Zhongyi
Xiao, Hongtao
Wang, Haojun
CLINICA CHIMICA ACTA, 2024, 561
[38] Therapeutic Applications of the CRISPR-Cas System
Kang, Kyungmin
Song, Youngjae
Kim, Inho
Kim, Tae-Jung
BIOENGINEERING-BASEL, 2022, 9 (09):
[39] Requirements for a successful defence reaction by the CRISPR-Cas subtype I-B system
Stoll, Britta
Maier, Lisa-Katharina
Lange, Sita J.
Brendel, Jutta
Fischer, Susan
Backofen, Rolf
Marchfelder, Anita
BIOCHEMICAL SOCIETY TRANSACTIONS, 2013, 41 : 1444 - 1448
[40] An overview of applications of CRISPR-Cas technologies in biomedical engineering
Jamehdor, Saleh
Zaboli, Kasra Arbabi
Naserian, Sina
Thekkiniath, Jose
Omidy, Honey Alef
Teimoori, Ali
Johari, Behrooz
Taromchi, Amir Hossein
Sasano, Yu
Kaboli, Saeed
FOLIA HISTOCHEMICA ET CYTOBIOLOGICA, 2020, 58 (03) : 163 - 173

← 1 2 3 4 5 →